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INTRODUCTION 
HISTORY OF THYROIDECTOMY 
The word goiter is derived from the Latin word “gutter” meaning 
throat or neck. Goiter is defined as an enlargement of the thyroid 
gland in the absence of autoimmune thyroid disease, inflamma-
tion, or malignancy [1]. Until the mid-nineteenth century sea-
weed was, because of its high iodine content, among the only 
feasible treatments for patients with goiter. Thyroid surgery was 
not possible due to the inadequate technical development of 
surgery [2, 3]. Early attempts at performing surgery were horrify-
ing and associated with very high mortality from bleeding and 
postoperative sepsis [3]. However, with the development of ether 
anesthesia (1846), antiseptics (1867), and artery forceps (1877), 
unhurried and safer dissections were now possible. Surgery for 
patients with large suffocating goiters was thereafter a risky, but 
achievable procedure [3, 4]. Theodor Billroth in Vienna (1877) 
published his leading work showing an unprecedented mortality 
rate of 8% after thyroidectomy by the use of antiseptic tech-
niques [2]. His achievements were further advanced by his 
mentee Theodor Kocher in Bern who would later receive the 
Nobel prize for his pioneering work in understanding thyroid 
disease (1909) [2, 4, 5]. The hallmarks of Kocher’s surgical tech-
nique were antiseptics, arterial ligation, and precise intracapsular 
thyroid dissection, which eventually reduced the mortality rate to 
below 1% [2, 4, 5]. Nonetheless, with the introduction of safer 
surgery, recognition of surgical complications (recurrent laryngeal 
nerve (RLN) paralyses, thyroid storm, myxedema, and hy-
pocalcemia/tetany) began to occur.  
Subsequent surgical achievements included the introduc-
tion of subtotal thyroidectomy by Thomas Dunhill (1920) which 
saved the lives of many young patient with severe hyperthyroid-
ism [4]. However, the pioneering work of these early surgeons 
was not well known across continental Europe, throughout the 
British Empire, or in the United States. In these territories, thyroid 
surgery was a dubious endeavor associated with high risks of 
mortality. Eventually, William Halsted of Baltimore (today John 
Hopkins hospital), George Crile from Cleveland (today Cleveland 
clinic), and Charles Mayo from Rochester (today Mayo Clinic) 
introduced the European advances to the United States and 
achieved a recorded RLN palsy rate of 0.3% and introduced para-
thyroid auto-transplantations [2, 4].  
Alongside these surgical achievements, other medical 
specialties also progressed and introduced: commercially availa-
ble thyroxine (1917), iodine prophylaxis (1920s), fine needle 
aspirations (1948), safe positive pressure ventilation (1965), 
better antithyroid drugs (1965), and B-mode ultrasound (US) 
(1970s). All this contributed to the pronounced progress, which 
has made most thyroid diseases  manageable in the present era 
[4]. 
BACKGROUND 
PATHOPHYSIOLOGY OF GOITER  
The role of the thyroid gland is to produce thyroid hormones 
[triiodothyronine and thyroxine (T4)], which are important for 
cellular activities such as cell growth and cell development [6, 7]. 
Approximately 12% of females in Denmark have an enlarged 
thyroid gland with nodules which is called nodular goiter [8]. 
Thyroid growth precedes the formation of nodules, and the nod-
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ules may eventually become autonomic, causing increased levels 
of thyroid hormones. However, the thyroid growth is subject to 
large variation among individuals ranging from extremely slow 
(no significant change in five years [9]) to a 20% nodule growth 
per year [10].  
The most important etiology for goiter worldwide is the 
direct correlation between insufficient iodine intake, iodine defi-
ciency, and the formation of goiter. Iodine deficiency causes low 
blood iodine levels, which leads to a reduction in T4 levels and 
increased secretion of thyroid stimulating hormone to restore T4 
concentration. The increased TSH secretion also stimulates thy-
roid follicular cell hyperplasia and hypertrophia leading to a dif-
fuse enlargement of the thyroid gland [11-13]. Denmark has 
traditionally been mildly to moderately iodine deficient with a 
goiter prevalence of 15-23% [14, 15], with, however, differences 
in prevalence between the eastern (15%) and western (23%) parts 
of Denmark [16]. The Danish iodine fortification program to cor-
rect the iodine deficiency commenced in the year 2000 and con-
sists of iodine-enriched household salt and iodine enriched salt in 
commercial bread. Urine iodine excretion levels have consequent-
ly risen [17], and subsequent the prevalence of goiter [18] and 
the known age-related increase in thyroid volumes have de-
creased in Denmark [19].  
Other factors also contribute to goiter-formation as goi-
ters are present in both iodine deficient and sufficient areas [20]. 
Genetic factors account for approximately 39% of the risk of 
developing goiter (95% confidence interval 0-79%) [21, 22]. In 
addition to iodine deficiency, tobacco smoking with the formation 
of thiocyanate (which inhibits iodine uptake) [23, 24], and insulin 
resistance [25-31] can also promote the formation of goiters. 
Further, environmental pollutants such as perchlorate and nitrate 
(inhibits iodine uptake), are rare causes for goiter formation [32].  
As the goiter progresses in volume, patients may develop 
a wide range of pressure symptoms [33]. This thesis is limited to 
patients with goiter who have symptomatic non-toxic, subclinical 
hyper- and hypothyroid goiter, and thereby only the anatomical 
pathology of goiter and not the impact of thyroid toxicity are 
investigated. 
COMPRESSIVE GOITER 
The compressive symptoms of goiter have a small, but significant-
ly negative impact on health-related quality of life (HRQoL), as 
shown in both generic and disease-specific quality of life ques-
tionnaires [34, 35].  
Swallowing abnormalities (effortful swallowing, globus-, 
and foreign body sensation) are among the most prevalent symp-
toms reported in 47-83% of patients with goiter referred for 
thyroidectomy [36-38]. The underlying pathophysiology is insuffi-
ciently understood as only a few studies have used objective 
examinations to understand this phenomenon. An explanation 
could be esophageal compression which is reported in 8-27% of 
patients referred for surgical treatment, however, with no clear 
definition of compression in this study [39, 40]. In addition, nearly 
40% of patients with goiter had increased esophageal transit time 
compared to healthy controls [41] and the esophageal transit 
time increased with increasing goiter volumes [42]. Another study 
found 50% of the patients undergoing total thyroidectomy had 
disturbances in esophageal motility [36]. However, these patients 
were examined by water perfusion systems, which makes it diffi-
cult to examine the upper esophagus related to the thyroid gland 
due to insufficient dynamic performance [43] and low spatial 
resolution of the system [44]. The interpretation of all above 
studies is hampered by selection bias as patients have been re-
cruited in different environments (primary care, local center, 
tertiary center, and surgical or medical hospital department) 
making it difficult to compare prevalence as the cohorts varies 
greatly. 
Limitations in tracheal airflow are frequently reported in 
patients with goiter and are suspected to be severely underesti-
mated [45]. Upper airway obstruction (UAO) is reported in 14-
31% of patients referred to tertiary centers for evaluation of 
goiter [46, 47], and in 26-60% of patients referred for thyroidec-
tomy [48-50]. Tracheal deviation is reported in 69-73% of patients 
with large goiters referred for thyroid surgery [39, 40, 51-57], 
whereas tracheal compression is seen in 9-58% of patients with 
cervical goiters [46, 51, 58], and in 35-73% of patients with sub-
sternal goiters [39, 40, 52, 54, 59]. Most studies in this area are 
hampered by ill-defined parameters of compression and inade-
quate information on cohort composition making generalization 
to the individual patient difficult. 
A few rare and extreme findings of goiter associated tis-
sue compression have been published. These reflect the close 
relationship of goiter to nearby structures other than the esopha-
gus and the trachea. They include reversible recurrent laryngeal 
nerve paresis [60], postoperative tracheomalacia [61, 62], trache-
al varices from superior vena cava syndrome [63], headache from 
carotid and vertebral compression [64], chylothorax from thoracic 
duct compression [65], brachiocephalic vein compression [66], 
acute upper limp ischemia from arterial compression [67], and 
internal jugular vein thrombosis [68]. 
As the symptoms of the goiter presented are essential in 
the decision to initiate treatment, the pre-treatment consultation 
and the presentation of all available treatment are of great im-
portance to align expectations of patients and physicians. 
THYROID SURGERY  
In patients with small goiters without symptoms of compression 
or cosmetic complaints, the watch-and-wait strategy can be op-
timal as further thyroid growth is by no means certain. Only a 
little is known with respect to the changes in HRQoL over time in 
patients with goiter of any size. The comparison of the various 
treatment options is therefore difficult and primarily focuses on 
post-treatment complications and surrogate markers for the 
beneficial effects.  
Surgery is by far the most widely used treatment option 
for goiter and thyroid lobectomy, subtotal thyroidectomy, and 
total thyroidectomy, are all acceptable strategies. Both thyroid 
lobectomy and total thyroidectomy have a low risk of secondary 
surgery. In contrast whereas subtotal thyroidectomy has a 3% - 
42% risk of goiter recurrence [69] and a three- to ten-fold higher 
risk of postoperative complications if a secondary  surgery is 
necessary [70]. Thus, thyroid lobectomy and total thyroidectomy 
are both effective treatment options, which remove pathological 
tissue, eliminates the risk of recurrence, and treat thyroid nodule 
autonomy [71-74].  
Thyroid surgery leads to significant improvements in 
HRQoL after treatment [75-78]. However, the interpretation of 
these results is hampered by mixed populations of patients with 
toxic and non-toxic goiter, and malignant thyroid disease com-
bined into single groups [75-77]. This makes it impossible to give 
strong conclusions on the benefits of surgery to patients with 
benign non-toxic goiter alone (knowledge gap 1). Swallowing 
symptoms are improved within six months after surgery in pa-
tients with goiter when examined by patient-reported outcomes 
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[37, 79-81], but only a little information is available regarding 
post-surgical objective swallowing function. A significant propor-
tion of patients undergoing surgery persist in having disturbances 
in esophageal motility in the weeks after surgery [36], but no long 
term results are available (knowledge gap 2). A few studies have 
shown improved inspiratory airflow following thyroidectomy [58, 
82]. However, the correlation between goiter volume, degree of 
tracheal compression, and/or deviation, and airflow is ambiguous. 
Further, the impact of these factors on HRQoL is unknown 
(knowledge gap 3) [83].  
The main caveats for surgery are the costs, required hos-
pitalization, risk of postoperative hypothyroidism, hypoparathy-
roidism, and unattended voice changes [61, 84, 85]. Most of 
these risks are specific for surgery, so while effective, surgery 
does have an unfavorable risk profile in comparison to non-
surgical interventions [86-93]). 
NON-SURGICAL TREATMENT MODALITIES 
Non-surgical treatment modalities have been present for many 
years. As previously mentioned, seaweed has been used for treat-
ing goiter, however, at present primarily radioiodine (131I ), laser 
thermal ablation (LTA), and radiofrequency ablation (RFA) are 
used, as Levothyroxine (LT4) is no longer recommended by spe-
cialist societies due to poor effect and side-effects  [20, 94]. 131I 
treatment works by causing damage to DNA, and thereby cellular 
necrosis and destruction of the follicular cells in the thyroid gland 
[95]. The first clinical results with 131I were published in 1946 [96, 
97]. 131I treatment reduces the goiter volume by 30-40% within 
the first year and by 50-60% within the first five years after 
treatment [98-106]. Both goiter symptoms and tracheal anatomy 
improves after 131I treatment [107]. So far, no data on swallowing 
function are available. 
131I treatment is hampered by the risk of goiter regrowth, 
which occurs in 10% of patients, whom needs a second dose for 
full effect [103, 108]. Recombinant human TSH can increase the 
uptake of I31I two- to four-fold [109, 110] and this allows for ei-
ther a lower dose of 131I or an increased goiter shrinkage. Howev-
er, this comes at a cost of an increased risk of side effects com-
pared to the conventional 131I treatment. The acute side effects of 
131I are thyroiditis, which occurs in 3-10% of patients, esophagitis, 
and an increase in thyroid volume from inflammation, thus in-
creasing the risk of airway compression. Late developing side 
effects may occur and these include a 20-60% risk of hypothyroid-
ism [109], a 1% risk of developing autoimmune hyperthyroidism 
[111], and lastly an unsettled risk of later malignancy, especially in 
younger individuals [112-114]. Nonetheless, for patients with 
contraindications to surgery or for those who reject surgical 
treatment, 131I is a relevant alternative.  
US-guided interventions include both LTA and RFA in addi-
tion to other more experimental treatments such as microwave 
ablation, which will not be discussed any further. These are prom-
ising treatment options as they report significantly fewer side 
effects in comparison to surgery [115, 116]. 
LTA works by emission of photons from excited atoms 
within the thyroid tissue, thereby creating a coagulative necrosis 
around the tip of a laser fiber when inserted into the thyroid 
gland. This procedure is performed in the outpatient clinic using 
local anesthesia. A recent systematic review identified a 13-82% 
reduction in thyroid nodule volume 12 months after treatment 
[117]. A large retrospective multicenter study which included 
1531 patients [115] had a mean nodular volume reduction of 
72±11% from baseline [mean 27±24 mL (range 1.4-216 mL) to 8±8 
mL (range: not described)] 12 months after treatment. Eighty-
three percent of the patients were treated with a single session 
and small, medium, and large nodules had similar volume reduc-
tions. Further, both local symptoms and cosmetic complaints 
were improved after treatment. Only eight of the 1531 patients 
(0.5%) experienced major complications, such as transient post-
operative voice changes, and no patients required surgical repair 
or overnight admission, which is a significant advantage in com-
parison to surgery [85, 115]. Nine patients experienced minor 
complications such as skin burns and hematoma [115].  
RFA works by inducing thermal energy (electromagnetic 
energy) into the thyroid nodule. This procedure takes advantage 
of a “moving shot” technique, internally cooled needles, and a 
transisthmic approach and is considered safe and feasible in solid 
“cold” nodules. It was performed in the outpatient clinic using 
local anesthesia and post-treatment nodule volume reductions 
ranged from 69%-93% 12 months after treatment [117]. Howev-
er, larger nodules required repeated treatments to secure suffi-
cient volume reductions [118]. RFA is not efficient in cystic nod-
ules due to the need for multiple repeated treatments [119]. A 
systematic review including 2421 patients with primarily benign 
non-autonomic nodules with a mean volume of 10.3 mL (range 
0.05 – 27.7 mL) [116], reported that 42 patients [1.35 % (95% CI 
0.89% - 1.81%)] experienced major complications. Of these, 31 
patients had transient voice changes and four experienced per-
manent voice changes (0.2%). Nodule rupture occurred in four 
patients, permanent hypothyroidism in one patient, and one 
patient had a temporary brachial plexus injury.  
US-guided interventions are especially relevant for small-
er goiters accessible by US and cutaneous needles due to a sim-
pler setup in comparison to surgery and a more favorable risk 
profile. Nonetheless, one should keep in mind that these results 
were hampered by an unknown selection bias, and a lack of long-
term data. Despite their relevance, no study has investigated the 
impact of US-guided interventions on essential outcomes after 
treatment such as HRQoL or surrogate markers such as swallow-
ing function, tracheal anatomy or tracheal airflow. 
PROSPECT THEORY 
From psychological investigations, humans are known to be risk 
adverse (Bernoulli [120]), meaning that humans in general avoid 
excessive risks. However, Kahneman et al. have modified this in 
their prospect theory [121] by showing that people’s perception 
of risks changes with their present standpoint, e.g. the weight 
patient places on decisions are not linear with in relation to the 
actual probabilities of events/complications. Low probabilities are 
weighed higher than they should be, and vice versa. This is ex-
pected to have consequences for patients in their choice of 
treatment for thyroid disease.  
Patients with malignant goiter may have a standpoint, 
which includes risk of death and this makes them more prone to 
accept the risks associated with surgical treatment to avoid the 
risk of death. However, the choice is by no means simple for 
patients with benign nodular goiter, as further progression of the 
disease is unknown for the individual patient, making it difficult to 
balance the risk of treatments to the risks associated with the 
disease. From prospect theory, patients with benign goiter would 
naturally chose a treatment option with the least risks and put 
less weight on treatment effectiveness as the non-surgical inter-
ventions do not exclude a later option for surgery. 
With the current level of evidence regarding the available 
treatment options for benign thyroid disease, it is difficult to help 
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patients make any evidence-based choice of treatment. Surgery is 
the most used modality with a well-known empirically based 
effect, but it is also the treatment modality with the highest rates 
of major complications. Only little is known on the effect of the 
other treatment modalities on HRQoL. However, as non-surgical 
treatments are less risky procedures, they are indeed of relevance 
to patients despite their reduced effectiveness in comparison to 
surgery.  
It is essential for all treatment options, including surgery, 
to provide relevant information on the benefits and risks associ-
ated with the specific treatment. This would allow patients, phy-
sicians and surgeons to make unbiased decisions between the 
available treatment modalities.  
KNOWLEDGE GAPS, AIMS, AND OBJECTIVES 
The primary indication for treatment of benign nodular goiter is 
HRQoL. However, as there is very limited information on im-
provements in HRQoL after surgical and non-surgical treatments, 
the optimal choice of treatment is a daily challenge for patients, 
physicians, and surgeons. In addition, how HRQoL is affected by 
changes in surrogate markers such as esophageal motility, and 
tracheal anatomy and airflow is also unknown. 
We therefore aim to limit the previous knowledge gaps 
(page 20) regarding impact of thyroidectomy on various aspects 
in patients with benign nodular goiter. Through three studies, we 
seek to investigate the following objectives: 
 
Knowledge gap 1 - Objective no. 1: 
• To investigate changes in disease-specific QoL following 
surgical treatment in patients with benign non-toxic nodular 
goiter. 
 
Knowledge gap 2 - Objective no. 2: 
• To examine the influence of thyroid surgery on swallowing 
symptoms and esophageal motility in patients with benign 
nodular goiter.  
 
Knowledge gap 3 - Objective no. 3: 
• To assess the effect of thyroidectomy on tracheal anatomy 
and tracheal airflow and correlate this to changes in HRQoL 
in patients with benign nodular goiter. 
 
METHODS 
STUDY DESIGN 
This project was a single-center, prospective, longitudinal, self-
controlled case-series made in a routine clinical care setting [122]. 
It was conducted at a tertiary university hospital, Odense Univer-
sity Hospital (OUH), using an unmasked design.  
For the first objective, investigating changes in HRQoL, a 
previously used control group from the general population was 
included [35]. However, for the remaining objectives an appropri-
ate and feasible control group could not easily be defined. Hence, 
no control group was recruited, thus making these studies self-
controlled case-series. Retrospectively, the optimal design would 
have been a comparative design with a control group of patients 
undergoing parathyroid surgery. As a consequence of the design, 
we will not give conclusions regarding the causal relationships 
between surgery and outcome. 
INCLUSION AND EXCLUSION CRITERIA 
The inclusion and exclusion criteria for the three studies are listed 
below. 
Inclusion criteria 
• Symptomatic benign nodular goiter undergoing thyroid 
surgery 
• Sufficient ability to read and understand Danish 
Exclusion criteria  
• Previous surgery to the neck 
• Present cancer or suspicion of cancer  
• Age below 20 or above 80 years 
• Neuromuscular disease including diabetes mellitus 
• Preoperative overt hypo- or hyperthyroidism 
• Paper I (HRQoL): Preoperative subclinical hypo- or hyper-
thyroidism 
• Paper II (MRI): Isthmectomy, pacemaker, or pregnancy 
 
The impact of the inclusion and exclusion criteria will be further 
described and discussed in section 4.4 Generalizability. 
PATIENT RECRUITING STRATEGY 
We designed the patient recruiting procedure according to best 
practice reports for randomized clinical trials (RCTs) [123-128]. 
The inclusion period ran from November 1 2014 to April 30 2016 
and was of sufficient length to adjust for seasonal and temporal 
factors. Recruitment of patients followed these principles: 
 
• The information of patients took place in the outpatient 
clinic immediately after the consultation with the thyroid 
surgeon. This was undertaken by the PhD fellow to mini-
mize disruption to the normal clinic, a well-known barrier to 
inclusion [125, 126].  
• The PhD fellow was chosen as the main recruiter of pa-
tients, as senior personnel would increase cost, but not the 
recruitment rate [127]. 
• A monetary incentive of DKr 150.00 per additional visit was 
provided to increase the recruitment rate [124, 127]. In ad-
dition, transportation costs were covered to minimize selec-
tion bias according to socioeconomic status. Substantial ef-
fort was put into creating an atmosphere for which 
enrolment did not require payment [123, 127]. 
• Patients who could not be informed in the outpatient clinic 
were contacted by phone after the consultation with the 
thyroid surgeon [128]. Before the phone-call, information 
material including a health specific questionnaire was 
mailed to the patient, as this is known to increase the re-
cruitment rate [127]. A “teaser” was written on the enve-
lope front including mentioning of university sponsorship as 
this increases recruitment rate and reduced loss to follow 
up [129]. 
• All examinations were scheduled around patient prefer-
ences and patients received reminders for upcoming visits. 
Waiting time between examinations was kept at a  mini-
mum, but, if necessary, it was used for the completion of 
questionnaires [123]. 
• We maintained a consistent focus on developing a strong 
patient – principal investigator relationship to increase the 
likelihood of return-to-follow up [123]. 
IMPLICATIONS OF STUDY FLOW  
Patients had the possibility to participate in four different studies 
(Figure 1). These included critical outcomes (post-operative voice 
changes), essential outcomes (change in HRQoL), and surrogate 
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outcomes (changes in esophageal motility, tracheal anatomy and 
airflow).  
 
Figure 1. Flow diagram includes all four studies originally intended in the PhD pro-
ject. Study 1 investigated changes in health-related quality of life (HRQoL) before 
and after thyroidectomy. Study 2 examined esophageal motility in relation to 
thyroidectomy. Study 3 assessed changes in tracheal anatomy and airflow after 
surgery. Study 4 examined voice function before and after surgery.  Items marked 
with grey are not included in the thesis.  
 
This thesis only covers three of the studies, as we await 
the remaining data on postoperative voice changes following 
thyroidectomy. If patients participated in all studies this involved 
a two-to-three hour examination program at baseline, a one-to-
two hour program three weeks after surgery, answering a HRQoL 
questionnaire by mail three months after surgery, and a two-to-
three hour examination six months after surgery. The examina-
tions were scheduled late in the afternoon to minimize waiting 
time. Clinical data including biochemical measurements were 
obtained by chart review. 
Patients followed the regular post-thyroidectomy follow 
up program including a consultation with a surgeon 10-12 days 
after surgery and an endocrinologist 2-3 months after surgery. In 
addition, to the study program and regular follow-up regime, 
patients were allowed to contact the PhD fellow at all times. All 
participants received a more intensive follow-up regime, including 
faster referrals to additional specialists than non-participating 
patients. A follow-up period of six months was chosen to account 
for the majority of the post-operative tissue healing phase, but 
balanced to reduce loss-to follow up [130]. 
HEALTH-RELATED QUALITY OF LIFE 
Only a few options existed for assessing changes in HRQoL after 
thyroidectomy. The Short Form (36) Health Survey and the Euro-
QoL five dimensions questionnaire were the most widely known 
generic questionnaires. These instruments covered broad catego-
ries of functioning and well-being and could be used to compare 
the relative burden of disease across various conditions. Howev-
er, both questionnaires have limited sensitivity for evaluating 
changes in HRQoL after treatment of goiter [131, 132]. By con-
trast, disease specific questionnaires emphasize symptoms, func-
tioning, and the patient’s perception of a narrowly-defined dis-
ease. Only the thyroid-specific patient-reported outcome 
measure (ThyPRO) was validated for the investigation of HRQoL in 
goiter patients [133-138]. This was more sensitive for examining 
changes in HRQoL than the generic questionnaires in this patient 
group [35] and was therefore used solely in this study. 
The ThyPRO was a thoroughly validated questionnaire in-
cluding evaluation of validity, reliability [133], responsiveness 
[139], cross-cultural effectiveness [135], and item misfits [136, 
137]. It consisted of 85 items covering physical symptoms specific 
to benign thyroid disease, but also non-specific effects related to 
impaired daily life. It measured HRQoL in the most recent four 
weeks [140-142]. The items were combined into 14 scales includ-
ing one single item scale covering Overall QoL (Figure 2). Each 
scale was linearly transformed to a scale from 0-100 points, with 
a higher score indicating more severe symptoms. After the initia-
tion of the project, an electronic version of the ThyPRO have 
become available [143]. 
 
 
Figure 2.The results from the thyroid-specific patient-reported outcome (ThyPRO) 
scale are often presented in a radar plot to allow faster interpretation of results and 
changes in scores over time. Scale scores range from 0-100 points, with 100 points 
indicating most severe symptoms. 
 
In cooperation with the developer of the ThyPRO Torquil 
Watt (TW) the eight items covering Graves orbitopathy (Eye 
Symptoms Scale) were removed to increase relevance for pa-
tients and to reduce answer times (to approximately 10 mins.), 
thereby seeking to increase the return rate of the questionnaire 
[144]. After our study was initiated, a shorter version of the 
ThyPRO questionnaire with only 39 questions have been devel-
oped based on the presence of mis-fitting items [145] This had a 
shorter completion time. However, the new version was not 
validated according to the standards of the original ThyPRO.  
We chose to utilize the baseline questionnaire immediate-
ly after patients had consented to thyroid surgery. It is unknown 
whether this had an impact on the individual scale scores of the 
ThyPRO. The patients might have answered differently, had the 
questionnaire been answered at the referral to surgery or includ-
ed in the letter with the time for the outpatient surgical consulta-
tion. Only a new study could determine this impact on the 
ThyPRO scale scores.  
Patients completed the questionnaire before surgery, 
three weeks after surgery, three months after surgery, and six 
months after surgery in order to assess various time points in the 
post-operative healing phase. The ThyPRO questionnaire three 
weeks after surgery was excluded after the completion of the 
study, as we failed to recognize the ThyPRO specifically measures 
the HRQoL in last four weeks, wherefore we have data-overlap at 
three weeks after surgery with the week before surgery. 
 
During the study we assessed if there was difference in 
scores between patients participating only in the ThyPRO ques-
tionnaire study and patients participating in additional studies 
(esophageal motility, tracheal anatomy and airflow, and voice 
function). Such differences would have implied a caring bias; 
however, we could not identify such an effect. 
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SUBJECTIVE SWALLOWING COMPLAINTS 
The persistent motility disturbances observed after thyroidecto-
my might be explained by postoperative fibrotic tissue formation 
or damage to the vagal nerve [36]. A patient- reported outcome 
in combination with objective analyses would be optimal to suffi-
ciently assess the impact of these factors on patients.  
Only a few questionnaires have been validated to assess 
the impact of swallowing dysfunction on HRQoL. For oropharyn-
geal dysphagia the Deglutitative Handicap Index, Dysphagia Hand-
icap Index, M.D. Anderson Dysphagia Inventory, and SWAL-QOL 
were available [146]. Of these only the SWAL-QOL had been 
extensively validated [146], however, it had not yet been trans-
lated into Danish. Hence, we therefore used the Goiter Symptom 
scale of the ThyPRO questionnaire as an alternative swallowing 
outcome as it included five items specific for swallowing (Figure 
3).  
 
 
Figure 3. A radar plot of the individual items of the Goiter Symptom Scale in the 
thyroid-specific patient-reported outcome (ThyPRO) questionnaire. The items scores 
range from 0-4 points, with 4 point indicating severe symptoms. Each item starts 
with: “During the last four weeks have you:”. 
 
The Goiter Symptom scale was thoroughly validated for 
patients with goiter and consists of 11 items. Each item starts 
with the question “During the last four weeks have you”. The five 
items specific for swallowing dysfunction are: 1) Pressure in your 
throat, 2) Sensation of a lump in your throat, 3) Need to clear 
your throat frequently, 4) Discomfort swallowing, and 5) Difficulty 
swallowing. The remaining six items covers other aspects of 
symptomatic goiter. The items were rated from 0 points (no 
symptoms) to 4 points (severe symptoms) on a Likert scale.  
The choice of using the Goiter Symptom scale instead of 
the SWAL-QOL questionnaire saved us a large amount of time 
validating the SWAL-QOL questionnaire. However, this choice 
might have hampered the validity of our swallowing specific 
outcome. The ability of the Goiter Symptom scale to estimate 
swallowing difficulties was assessed by adding three Visual Ana-
logue Scales (VAS) scores to all patients participating in the exam-
ination of swallowing dysfunction. The questions were specific for 
swallowing symptoms. 
 
Question 1: How often do you have a sensation of a lump in your 
throat?  
Question 2: How often do you feel discomfort while swallowing?  
Question 3: How often do you have difficulties swallowing?  
 
The VAS scores ranged from 0-100 points (0-100 mm) 
with a score of 0 points equaling “never” and one of 100 points 
equaling “always”. After completion of the study the VAS scores 
were correlated with the Goiter Symptom scale and we found a 
high correlation (r > 0.60) between these scores and the Goiter 
Symptoms scale (p<0.001). 
SWALLOWING FUNCTION 
To objectively assess swallowing function in patients with goiter, 
barium esophagogram, impedance measurements, and high 
resolution esophageal manometry (HREM) were available. The 
most clinically relevant objective parameter was the bolus transit. 
This could be assessed by the barium esophagogram or by im-
pedance measurements. The barium esophagogram was non-
invasive, could be performed quickly, and illustrated esophageal 
anatomical deformities well [147]. Impedance measurement was 
invasive, but provided physiological information of the bolus 
transit in contrast to imaging alone [147]. However, neither of 
these could evaluate the esophageal motility which could be 
affected pre-surgically by external compression from the goiter, 
and post-surgically by vagal nerve affection or fibrotic tissue 
formation. Hence only HREM was considered for the present 
study. HREM was an invasive catheter based examination with 36 
pressure censors (each consisting of 12 individual micro transduc-
ers) capable of recording rapid pressure changes from the esoph-
ageal contraction around the censors [148]. The censors were 
spaced one cm apart, thereby covering the entire length of the 
esophagus from the pharynx to the stomach after insertion of the 
catheter through the nose. The data were plotted in a three-
dimensional color coded topographic plot, with distance between 
sensors plotted on the y-axis, time on the x-axis (seconds), and 
pressure amplitude on the z-axis (marked with different colors) 
(Figure 4). The esophageal motility was measured from the 
esophageal contraction around individual sensors. This allowed 
for rapid real-time visual interpretations of the swallowing func-
tion. 
 
 
Figure 4. Left image shows a wet swallow with normal esophageal motility (A). Right 
image shows a  wet swallow in a patient with a minor disorder of peristalsis charac-
terized by ≥50% ineffective swallows (B). Upper esophageal sphincter (UES), lower 
esophageal sphincter (LES), integrated relaxation pressure (IRS), contractile front 
velocity (CFV), and distal latency (DL) 
Patients fasted for five hours before examination as the 
insertion of the catheter was associated with some discomfort 
and a risk of aspirating gastric content.  
With the catheter correctly placed, patients completed 15 
wet swallows, each of 5 mL water with 20-30 seconds between 
the swallows. For standardization, all examinations were per-
formed in the supine positions [43].   
A few parameters were of special relevance to esophageal 
manometry and for evaluating the impact of thyroidectomy (Fig-
ure 4). Important esophageal landmarks were the upper esopha-
geal sphincter (UES) of which both the resting and contraction 
pressure were of interest. Also, the lower esophageal sphincters 
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(LES) resting pressure and relaxation were essential parameters. 
Relaxation could not be measured directly, so it was measured by 
the integrated relaxation pressure (IRP) (based on the LES pres-
sure after initiation of a swallow in the UES [149]. To evaluate the 
propagation of the esophageal pressure waves, both the contrac-
tion front velocity (CFV), a measure of the peristaltic velocity in 
the smooth muscle esophagus, and the distal latency (DL), a 
measure of the time from opening of the UES to termination of 
the esophageal pressure wave, were of relevance [149]. Lastly, 
the mean contraction amplitude of the smooth muscle esophagus 
was measured by the distal contractile integral (DCI) [149].  
The PhD fellow performed all HREM procedures inde-
pendently. Before initiation of the study, the fellow shadowed 
consultant Søren Kruse-Andersen (SKA), who was experienced in 
the procedure, for four days. All procedures were thereafter 
performed independently, with the possibility of guidance by SKA. 
A few of the initial patients were excluded due to inadequately 
performed procedures e.g. insufficient saved files, missed calibra-
tion, and equipment malfunction.  
After completion of all examinations the data were ana-
lyzed blindly in cooperation with MD Simone Markøw (SM), who 
previously had performed HREM examinations and interpreta-
tions independently as a laboratory technician. Initially, the ten 
most representative swallows were identified. Then each swallow 
was examined individually and relevant structures marked. Finally 
the software calculated mean values based on the ten swallows. 
The interpretation of the esophageal motility was conducted 
according to the Chicago classification v. 3.0 an international 
classification system of esophageal motility disorders [150, 151]. 
The HREM catheters have shown some challenges with 
reproducibility [44] as a pressure drift of sensors have been ob-
served in the upper esophagus [152]. The pressure drift was seen 
during the catheter’s life span of 200 examinations. We per-
formed 75 examinations over a two-year period, not near to the 
catheter’s’ maximum capacity, but it is unclear if the pressure 
drift affected the results at the six months follow-up. To limit the 
impact, the same catheter was used in all patients. 
AIRFLOW LIMITATIONS 
Limitation in tracheal airflow is considered an important physio-
logical parameter to assess in patients with goiter as UAO might 
be underreported [45]. However, how to assess this was worth a 
few thoughts. A large goiter might cause UAO affecting the larynx 
and extra- and intrathoracic portion of the trachea. According to 
Poisseulle’s law, air flow is fourfold proportional to tracheal radi-
us, thus any compression of the trachea would lead to a substan-
tial change in airflow. However, this can be modified, as the tra-
cheal rings in particular are at risk of collapsing during inspiration 
from the negative transmural pressure gradient across the tra-
cheal wall. This is less critical during expiration with pre-stenotic 
(i.e. intrathoracic) air pressure being above atmospheric pressure. 
A regular pulmonary function test was vital for assessing 
airflow in patients with goiter. However, it needed to be extend-
ed with measurements of inspiratory airflow to fully assess the 
impact of goiter. A flow-volume loop (FVL) covered both expirato-
ry and inspiratory airflow and consisted of a rapid full inspiration, 
immediately followed by an expiration of maximum force until no 
more air could be expired. This was followed by a quick maximum 
inspiration [153] (Figure 5). Measures of expiration [peak flow 
(PEF), forced expiratory volume in one second (FEV1), and forced 
expiratory flow at 50% of forced vital capacity (FVC) (FEF50%)] 
could be assessed in combination with a measure of inspirations 
[forced inspiratory flow at 50% of FVC (FIF50%)]. It had been sug-
gested that the ratios FEF50%/FIF50% and FEV1/PEF could reflect the 
presence of UAO in patients with goiter. 
 
 
Figure 5. The left illustration is a normal flow volume loop curve, whereas the right 
illustration shows a patient with upper airway obstruction with flattening of expira-
tory flow and inspiratory flow. Peak flow (PEF), forced vital capacity (FVC), Forced 
expiratory flow at 50% of FVC (FEF50%), and Forced inspiratory flow at 50% of FVC 
(FIF50%). 
 
This was a standardized procedure with patients posi-
tioned comfortably in a chair with a straight back and a slightly 
extended neck. The procedure required careful instructions and 
some training to perform it correctly. Each patient performed the 
procedure a maximum of six times, and the three best procedures 
were used for further analyses. As the examination required 
maximum effort from the patient there was a limit on how many 
times the patient could perform the examination to avoid exhaus-
tion and reduced data quality.  
To secure sufficient training of the PhD fellow, he was 
paired with MD Jeppe Faurholdt Lauridsen (JFL) who was trained 
in the procedure. They performed the first 25 procedures in co-
operation, after which the PhD fellow would perform the proce-
dures independently. No analyses of inter- and intra-observer 
variation between JFL and the fellow were undertaken.  
TRACHEAL ANATOMY 
To understand the limitations seen airflow in patients with goiter, 
the goiter volume and its relation to the trachea were important 
anatomical parameters to assess. US, computed tomography (CT), 
and magnetic resonance imaging (MRI) could all be used for 
visualization of the thyroid and trachea [39, 40, 52, 54, 59, 154, 
155]. Plain radiographic images of the trachea were considered 
obsolete, due to poor correlation to airflow and CT determined 
tracheal cross-sectional area  [154].  
Despite US being used for measuring thyroid volume, thy-
roid nodularity, and the thyroid relation to trachea in daily clinic, 
it was insufficient to show tracheal compression in comparison to 
both CT and MRI [156, 157]. Only MRI had a good delineation of 
surrounding structures. However, the disadvantages of MRI in 
comparison to the other modalities were: the confined space, 
high noise level, long scanning time, and forceful magnetic field 
which excluded patients with pacemakers. 
Experienced radiographic technicians performed all the 
MRI scans, whilst the PhD fellow performed all measurements of 
thyroid and tracheal parameters. Prior to performing measure-
ments, the PhD fellow had a training session with consultant 
Peter Bøgeskov Andersen (PBA) and they evaluated ten pre- and 
postoperative scans for incongruence before making the final 
measurements.  
Each patient had thyroid volume, tracheal volume, great-
est thyroid encirclement of trachea, greatest tracheal deviation 
from the midline, smallest cross-sectional area of the trachea 
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(SCAT), cross-sectional area of the trachea two cm above the 
carina (CCAT), and the tracheal narrowing in percent ((CCAT-
SCAT)/CCAT) measured (Figure 6). 
 
 
Figure 6. MRI images before and after surgery for a patient with a goiter of 125 mL. 
Red dotted line illustrates the tracheal cross-sectional area, white full line illustrates 
the midline, and yellow dotted line shows the thyroid cross-sectional area. Cross-
sectional areas can be multiplied with slide thickness to reach thyroid and tracheal 
volume. 
 
The PhD fellow was judged capable of assessing the tra-
cheal parameters independently from his previous research using 
microCT for bone volume measurements [158]. No blinding of the 
MRI scans was applied, as the estimations of tracheal and goiter 
volume required continuous comparison of pre- and post-
thyroidectomy images. This might have introduced bias in the 
results as the PhD fellow was by nature not blinded to the pur-
pose of the study. In addition, inter- and intra-observer meas-
urement analyses were not performed, as MRI had previously 
shown good properties for the assessment of goiter volume [155].  
 
DATA PRESENTATION AND DATA RELIABILITY 
Cohen’s effect size (ES) was used to present the strength of post-
thyroidectomy  changes as a substantive effect on a scale with 
little variation, i.e. a small standard deviation was likely to have a 
greater clinical impact than on a scale with large existing variation 
[144, 159]. This was reflected in ES statistics (mean change of pre- 
and post-surgical observations divided by standard deviation at 
baseline) in contrast to statistical significance. According to Cohen 
et al. ES of 0.2-0.5 was defined as a small change, 0.5-0.8 as a 
moderate change, and a values > 0.8 as a large change [144, 159]. 
This standardized change could be compared across studies. 
To increase data reliability of the 338 variables collected 
for this study, data collection was set-up in the Research Electron-
ic Data Capture (REDCap) [160] program developed by the Van-
derbilt University Medical Center. REDCap was a web-based 
application designed to support data capture for research studies. 
We used both value limitations and double data entry on all 
variables to secure a reliable dataset reflecting the actual study 
results [161]. 
 
RESULTS 
STUDIES AT A GLANCE 
The results will be introduced as a summery with the full results 
presented in the individual papers. Initially, the study design, 
participants, and methods used are described (Table 1). This is 
followed by a presentation of internal and external validity and a 
Statistical Overview. Lastly selected results from Papers 1 - 3 are 
presented (Tables 2 -4).  
Table 1. Overview of study design, participants, and methodology in the included 
papers. 
Health-related quality of life (HRQoL), Thyroid-specific patient-reported outcome 
(ThyPRO), Grade of recommendation according to Centre for Evidence-Based 
Medicine (*), Oxford [162], High resolution esophageal manometry (HREM), Magnet-
ic resonance imaging (MRI), and Flow volume loop curve (FVL). 
 
INTERNAL VALIDTY 
Paper I HRQoL 
• HRQoL assessed by a thoroughly validated patient reported 
outcome (ThyPRO). 
• Study group compared with a large control group from the 
general population. 
• All questionnaires answered without supervision from 
health care personnel. 
• A linear mixed model used to account for patient specific 
variation. 
• Caring bias analyzed, and not present. 
Paper II HREM 
• The Goiter Symptom scale is not specifically validated for 
assessing swallowing symptoms. 
• No control group included.  
• Manometric data analyzed blind by experienced personnel. 
Participants Cohort Methods  
Paper I HRQoL 
Study group: 
106 patients with 
benign nodular 
goiter (86% fe-
males).  
Age: 51 ± 13 
Control group: 
739 participants 
from the general 
population (81% 
females). Age: 50 
± 16 
Prospective cohort 
study 
Study group: 
Continuously includ-
ed patients with non-
toxic goiter undergo-
ing isthmectomy, 
thyroid lobectomy or 
total thyroidectomy. 
Control group:  
Participants from the 
Danish civic registry.  
Study group: 
ThyPRO ques-
tionnaire before, 
three months 
after, and six 
months after 
surgery. 
Control group: 
ThyPRO ques-
tionnaire sent by 
mail and an-
swered once [35].  
Paper II HREM 
33 patients with 
benign nodular 
goiter (74% fe-
males).  
Age: 60 ± 12 
Self-control-led case-
series  
Continuously includ-
ed patients with non-
toxic, subclinical 
hypothyroid, and 
subclinical hyperthy-
roid goiter undergo-
ing isthmectomy, 
thyroid lobectomy or 
total thyroidectomy. 
Goiter Symptom 
scale of the 
ThyPRO ques-
tionnaire and 
HREM performed 
at baseline and 
six months after 
surgery. 
Paper III MRI 
65 patients with 
benign nodular 
goiter (64% fe-
males).  
Age: 55 ± 13 
Self-controlled case-
series 
Continuously includ-
ed patients with non-
toxic, subclinical 
hypothyroid and 
subclinical hyperthy-
roid goiter undergo-
ing thyroid lobecto-
my or total 
thyroidectomy. 
MRI and FVL and 
selected scales 
from the ThyPRO 
questionnaire at 
baseline and six 
months after 
surgery. 
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• No use of a supplementary technique to confirm HREM 
findings. 
Paper III MRI 
• Appropriate choice of image modality. 
• No control group recruited. 
• No blinding or inter-/intra observer variation performed. 
• FVL examinations performed in cooperation with experi-
enced personnel. 
• Inclusion of a validated HRQoL questionnaire 
 
EXTERNAL VALIDTY 
Paper I HRQoL 
• 106 of 243 patients (44%) seen in the outpatient clinic with 
euthyroid goiter completed the study. 
• 739 of 1200 participants (62%) from the control population 
answered the ThyPRO once. 
• The inclusion rate of the available patients after application 
of exclusion criteria was 89% with a drop-out rate of 10% six 
months after surgery. 
Paper II HREM 
• 33 of 271 patients (12%) with nodular goiter seen in the 
outpatient clinic completed the study. 
• The inclusion rate after exclusion criteria was 29% of availa-
ble patients with a drop-out-rate of 20% at six months after 
surgery. 
Paper III MRI 
• 65 of 267 patients (24%) with nodular goiter seen in the 
outpatient clinic completed the study. 
• The inclusion rate after exclusion criteria was 52% with a 
drop-out rate of 13% six months after surgery. 
SAMPLE SIZE CALCULATION AND STATISTICAL METHODOLOGY 
Paper I HRQoL 
• The sample size of the study group was calculated at 104 
patients based on a paired sample. This is based on a small-
est clinically relevant difference between ThyPRO scale 
scores of five points with a standard deviation of 18 points 
[35]. 
• A non-paired t-test was used to compare ThyPRO scores 
between the study group and control group at baseline and 
six months after surgery.  
• A linear mixed model was used to assess the impact of 
thyroidectomy on ThyPRO scores in the study group with 
each patient having three measurements (baseline, three 
months, and six months after surgery.  
• A multiple regression analysis was used to evaluate the 
impact of age, sex, weight of the removed goiter, and pre-
vious radioiodine treatment on ThyPRO score changes in 
the study group. 
Paper II HREM 
• The power calculation was based on improvements in UES 
dysmotility after surgery, as examined by water manometry 
[36]. Preoperatively 25% of patients had UES dysmotility, 
and this was reduced to 6% 30-45 days after surgery [36]. 
Using this difference 30 patients were required to complete 
the investigation. 
• The Wilcoxon signed rank test was used to assess change in 
the Goiter Symptom scale of the ThyPRO questionnaire due 
to non-transformable skewness.  
• A paired t-test was used to compare the HREM data before 
and six months after surgery. 
• A multiple linear regression analysis was used to analyze the 
impact of age, sex, weight of the removed goiter, and surgi-
cal procedure on motility parameters and to assess the mo-
tility parameters’ influence on Goiter Symptoms. 
Paper III MRI 
• The sample size was calculated at 58 patients, based on a 
paired sample with changes in SCAT of 0.15±0.4 cm2 after 
treatment with 131I [100, 104, 163].  
• A paired t-test was used to compare tracheal, respiratory, 
and HRQoL parameters before and six months after surgery.  
• A multiple linear regression analysis was used to evaluate 
the impact of age, sex, and thyroid volume on preoperative 
tracheal parameters. 
• A multiple regression analysis was used to evaluate the 
correlations between tracheal narrowing, FVL, and HRQoL 
parameters using age and sex as independent variables. 
Paper I (HRQoL)  
 
Study group Before surgery 
Six months 
after sur-
gery 
p-
valuea 
Effect 
size 
Goiter Symp-
toms 40 ± 21 8 ± 10 <0.001 1.52 
Hyperthyroid 
Symptoms 20 ± 17 12 ± 13 <0.001 0.48 
Hypothyroid 
Symptoms 21 ± 20 14 ± 17 <0.001 0.35 
Tiredness 50 ±  26 33 ± 24 <0.001 0.60 
Cognitive 
Complaints 21 ± 21 14 ± 19 <0.001 0.36 
Anxiety 20 ± 21 8 ± 13 <0.001 0.54 
Depressivity 27 ± 21 17 ± 15 <0.001 0.42 
Emotional 
Susceptibility 29 ± 23 20 ± 21 <0.001 0.37 
Impaired 
Social Life 6 ± 13 5 ± 13 0.52 0.08 
Impaired 
Daily Life 12 ± 19 7 ± 17 0.008 0.28 
Impaired Sex 
Life 13 ± 24 12 ± 23 0.38 0.08 
Cosmetic 
Complaints 20 ± 22 9 ± 14 <0.001 0.48 
Overall Quali-
ty of Life 35 ± 31 12 ± 25 <0.001 0.74 
Control 
group Cross-sectional score 
p-
valueb 
p-
valuec 
Goiter Symp-
toms 5 ± 9 <0.001 <0.001 
Hyperthyroid 
Symptoms 12 ± 14 <0.001 0.76 
Hypothyroid 
Symptoms 14 ± 16 <0.001 0.99 
Tiredness 35 ± 21 <0.001 0.35 
Cognitive 
Complaints 14 ± 17 <0.001 0.90 
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Anxiety 13 ± 16 <0.001 0.005 
Depressivity 21 ± 18  0.01 0.03 
Emotional 
Susceptibility 23 ± 19 0.005 0.17 
Table 2: Selected results (mean ± SD) from Paper I (HRQoL). Study group (n=106) and 
control group (n=739). [164] Study group baseline vs. 6 months after surgery using a 
linear mixed model (a), Control group vs. study group baseline using a non-paired t-
test (b). Control group vs. study group at 6 months after surgery using a non-paired 
t-test (c). Changes with an effect size of 0.2-0.5 were defined as small, values 0.5-0.8 
as moderate, and values > 0.8 as large. Health-related quality of life (HRQoL). 
Short description of results 
The study group had a reduced HRQoL at baseline in all assessed 
ThyPRO scales in comparison to the control group (p-values and 
ES seen in Table 4). The study group experienced pronounced 
improvements in HRQoL in the first three months after surgery. A 
large improvement was observed in the Goiter Symptom scale at 
both three months and six months after surgery. Overall QoL 
improved moderately at three months, but improved additionally 
at six months after surgery. The remaining scores for Hyperthy-
roid Symptoms, Hypothyroid Symptoms, Tiredness, Cognitive 
Complaints, Anxiety, Depressivity, and Cosmetic Complaints 
demonstrated only small improvements at three months after 
surgery. The Tiredness and Anxiety scales progressed to moderate 
improvements six months after surgery.  
Six months after surgery, the study group had more Goi-
ter Symptoms, but less Anxiety in comparison to the control 
group. There was no difference between the remaining scales and 
the control group. 
Using multiple linear regression analyses, increasing age 
was associated with less relief in Goiter Symptoms after surgery (-
0.45 points/year, p=0.003), but older individuals also had less 
Goiter Symptoms at baseline (-0.35 points/year, p=0.03). Female 
patients experienced more relief in Goiter Symptoms (11 points 
more than males, p=0.048). However, female patients had more 
Goiter Symptoms than males prior to surgery (15 points, 
p=0.007). A goiter above the median size of 35 grams was associ-
ated with a greater relief of Cosmetic Complaints (11 points, 
p=0.003), but these patients also had more Cosmetic Complaints 
prior to surgery (11 points, p=0.01). No other scales were affected 
by the goiter weight. 
PAPER II (HREM)  
Table 3. Selected results [median (range) and mean ± SD] from paper II (HREM) 
(n=33). [165] High resolution esophageal manometry (HREM), Upper esophageal 
sphincter (UES), Integrated relaxation pressure (IRP), Lower esophageal sphincter 
(LES), Distal latency (DL), Contractive front velocity (CFV), and Distal contractile 
integral (DCI). Effect sizes of 0.2-0.5 were defined as small changes, 0.5-0.8 as 
moderate changes, and values > 0.8 as large changes. 
 
Short description of results 
The Goiter Symptom scale showed a large improvement six 
months after surgery compared to baseline (p-values and ES seen 
in Table 5). All motility parameters were within the limits of nor-
mal swallowing before surgery [166], and only the UES basal 
pressure increased after surgery (p=0.04). The remaining motility 
parameters, i.e. DL, UES IRP, CFV, and DCI showed no significant 
change.  
One patient (3%) fulfilled the criteria for having a minor 
peristaltic disorder, defined as >50% weak or failed swallows 
before surgery, while two patients (6%) fulfilled these criteria 
after surgery. No patient had major peristaltic disorders either 
before or after surgery. 
With regression analyses we demonstrated a significantly 
larger reduction in UES basal pressure (9.6 mmHg, p=0.047), peak 
pressure 4 cm below the UES (32.4 mmHg, p=0.03), and of the 
DCI (1306 mmHg-cm-s, p=0.04), in patients undergoing total 
thyroidectomy in comparison to patients undergoing hemithy-
roidectomy or isthmectomy after surgery. 
No correlations between the pre- and postoperative Goi-
ter Symptom scores and motility parameters, presence of motility 
disturbances, or goiter weight, were present. 
PAPER III (MRI) 
Table 4. Selected results [median (range) and mean ± SD] from paper III (MRI) 
(n=65).[167] Magnetic resonance imaging (MRI), Smallest cross-sectional area of the 
trachea (SCAT), Peak flow (PEF), and Forced inspiratory flow at 50 % of forced vital 
capacity (FIF50%). Effect sizes of 0.2-0.5 were defined as small changes, 0.5-0.8 as 
moderate changes, and values > 0.8 as large changes. 
 Short description of results 
Tracheal narrowing, tracheal deviation, and SCAT experienced 
moderate improvements six months after surgery (p-values and 
ES seen in Table 6). Tracheal narrowing, tracheal deviation, and 
SCAT at baseline correlated strongly with the initial goiter volume 
(p<0.001). After surgery, tracheal narrowing, tracheal deviation, 
and SCAT improved moderately, and tracheal volume underwent 
a small increase. Improvements in tracheal parameters all corre-
lated strongly with the reduction in thyroid volume.  
Postoperatively, a small, but highly significant, improve-
ment was found in FIF50%. Also small significant declines in the 
FEF50%/FIF50% (ES=0.29, p=0.001) and FEV1/PEF (ES=0.39, p=0.002) 
ratios were observed which might reflect UAO. Tracheal narrow-
ing correlated with the initial respiratory parameters. A 1% in-
crease in tracheal narrowing led to a decrease of 0.03 L/min in 
PEF (p=0.003) and a 0.02 L/min decrease in in FIF50% (0=0.01). 
Parameters Before surgery 
Six months 
after surgery p-value 
Goiter Symptom 
scale 39 (2-61) 5 (0-52) <0.001 
UES basal pressu-
re (mmHg) 70.6 ± 27.7  87.7 ± 43.2  0.04 
UES IRP (mmHg) 5.3 ± 7.3 2.8 ± 6.2  0.12 
LES basal pressu-
re (mmHg) 23.4 ± 17.0  25.4 ± 18.4  0.59 
LES IRP (mmHg) 8.7 ± 11.0 10.5 ± 9.6 0.37 
DL (s) 3.5 ± 0.6 3.6 ± 0.8 0.15 
CFV (cm/s) 4.1 ± 1.4 4.1 ± 1.9 0.94 
DCI (mmHg-cm-s) 1652 ± 1063 1750 ± 1660  0.25 
Parameters Before surgery 
Six months 
after sur-
gery 
p-value Effect size 
Tracheal narro-
wing (%) 39 (0-90) 29 (0-54) <0.001 0.67 
Tracheal devia-
tion (mm) 12 ± 7 8 ± 4 <0.001 0.61 
SCAT (cm2) 1.5 ± 0.5 1.8 ± 0.5 <0.001 0.73 
PEF (L/min) 7.5 ± 2.2 8.0 ± 1.9 0.03 0.19 
FIF50% (L/min) 4.8 ± 1.4 5.3 ± 1.5 <0.001 0.32 
Goiter Symp-
toms 40 ± 21 10 ± 11 <0.001 1.37 
Tiredness 48 ± 25 35 ± 24 <0.001 0.52 
Anxiety 20 ± 21 7 ± 12 <0.001 0.59 
Impaired Daily 
Life 13 ± 19 7 ± 16 0.48 0.29 
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From selected scales of the ThyPRO questionnaire, the 
Goiter Symptoms score experienced a large improvement six 
months after surgery, whereas the Tiredness scale changed mod-
erately. The Anxiety scale also had a moderate improvement, but 
the change in the Impaired Daily Life scale was insignificant. How-
ever, using multiple regression analyses, the improvement in 
tracheal narrowing correlated  positively with improvement in the 
Impaired Daily Life scale with a coefficient of 0.33 point im-
provement per 1% decrease in tracheal narrowing (p=0.03). The 
baseline tracheal narrowing and inspiratory flow did not correlate 
with pre-treatment HRQoL. 
DISCUSSION 
This PhD thesis addresses two overall themes not previously 
extensively investigated: first, the capability of thyroidectomy to 
relieve symptoms of goiter and second, the impact of thyroidec-
tomy on anatomical/physiological parameters commonly affected 
by goiter i.e. the esophageal compression and swallowing func-
tion and trachea narrowing and airflow. Both themes are original 
and having news value for the thyroid scientific community.  
This section will primarily focus on strengths and limita-
tions to the individual studies. For a thorough discussion of the 
results in relation to existing literature it is referred to the indi-
vidual papers. This is to avoid duplication of text in thesis and 
paper.  
THYROIDECTOMY AND SYMPTOM RELIEF 
Patients with goiter experienced profound improvements in 
symptoms of goiter both three and six months after thyroidecto-
my. These gains, ranged from small to large on most of the 13 
ThyPRO scales. Only the Sex Life and Social Life scales did not 
improve after surgery. At six months after surgery, all scores in 
the study group were close to the scores of the general popula-
tion.  
Three factors support the view that these results are 
trustworthy. First, the majority of improvements took place dur-
ing the first three months after surgery wherefore symptom 
relieve was closely related to the surgical procedure and not to 
any later unknown effect. Second, the patient group had scores 
similar to the general population six months after surgery. This 
indicates that it is the removal of goiter which was the cause for 
improvement and not an underlying placebo effect of surgery. 
Third, other studies with different cohort compositions have also 
identified improvements in HRQoL after thyroidectomy which 
does support our findings [75-77]. Further, the use of a thorough-
ly validated patient-reported outcome measure, answers without 
supervision from health care personnel, a large control group, 
and multiple examination points indicates good internal validity 
of the study. In addition, our finding is representative of the study 
population, from the inclusion rate of 89% and a loss to follow-up 
of only 10% six months after surgery.  
When using multiple regression analyses, various sub-
groups scored differently on the ThyPRO questionnaire. Women 
experienced more symptoms from smaller goiters in comparison 
to men. The underlying cause for this effect is unknown. It could 
be speculated that a larger neck in men makes them able to 
accommodate a larger goiter before presenting symptoms. How-
ever, this is pure speculation and the findings could also be asso-
ciated with an underlying selection bias where men may delay 
their treatment of goiter longer than women. Younger individuals 
had more symptoms when compared to older individuals. This 
might be explained by different perception of disease between 
age groups. However, there is an increase in tracheal calcification 
with age making the trachea of an older individual able better 
able to withstand external compression of goiter compared to a 
non-calcified trachea of younger individuals which might explain 
some of this finding. In addition, the exclusion criteria requiring 
first time thyroid surgery did in fact lead to the exclusion of older 
individuals who had previously been operated upon, who might 
have differed from higher age population who were included. The 
relatively poor correlation between weight of the goiter and the 
symptoms presented by patients was also of interest. The size of 
the goiters was only associated with cosmetic complaints indicat-
ing that the symptoms from goiter are not directly related to 
goiter volume and might instead be caused by confounding fac-
tors such as local esophageal compression or individual differ-
ences in perception of disease. 
No study has investigated the impact of 131I, LTA or RFA 
treatment on HRQoL, hence it is not possible to compare the 
effects of these treatments to surgery. However, a study investi-
gating the impact of treatment i.e. ethanol sclerotherapy, 131I, 
and surgery combined into one group, identified much less im-
provement in symptoms than seen in our paper I (HRQoL) [35]. 
The authors concluded that patients with goiter had persistent 
health deficits after intervention. We found no evidence for such 
a conclusion after surgical intervention alone, indicating that 
surgery is a very effective treatment in relieving symptoms of 
benign non-toxic goiter.  
Limitations 
Despite this study being the largest to use the ThyPRO question-
naire to investigate changes in HRQoL following thyroidectomy, it 
was still underpowered with regard to investigating many inter-
esting aspects of goiter. The results for individual surgeons, the 
impact of post-operative TSH adjustments, surgical complications, 
and thyroid volume would all be relevant for future studies and 
quality control.  
 
Our control group was not specifically recruited for this 
study and thus differs from the study cohort. The control group 
had only malignancy as an exclusion criterion and included pa-
tients from the age of 18 years, whereas we had a lower age limit 
of 20 years and used multiple exclusion criteria. Additionally, the 
response rate of the control group was 62% compared to our rate 
of 89%, so many control persons were not investigated. This 
selection bias between cohorts might explain some of the minor 
differences we observed between the study cohort and the con-
trol group six months after surgery. Further, our control group 
contained no longitudinal information, hence it is difficult to 
interpret some of the small changes seen in the ThyPRO scores 
over time.  
Another possible bias comes from the Hawthorne effect 
where the participant’s knowledge of being observed has a posi-
tive impact on the results of the observed procedure [121]. There 
was no evidence of a caring bias in this study, but all patients 
participating in the HRQoL study might have received superior 
service and treatment throughout the study, as hospital person-
nel also felt observed. Our results might thus have been more 
positive than if they had been implemented using blinded hospi-
tal staff. 
While the questionnaire has been thoroughly validated, 
there are still considerations relevant for the interpretation of our 
results. First, we put a major focus on the Goiter Symptoms scale 
in both Paper I (HRQoL) and Paper II (HREM). However, on this 
scale four of the 11 items are subjected to differential item func-
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tioning, making the results dependent on cohort composition, 
thereby reducing the generalizability of the results [136]. In addi-
tion, 11 items of the ThyPRO were found potentially mis-fitting by 
confirmatory factor analyses [137]. Despite, these considerations 
only having a small impact on the final results, the compiler of the 
questionnaire has recommended these items be removed in a 
subsequent version (ThyPRO-39) [145].  
Implications 
• The study provides clinically relevant information for pa-
tients, physicians, and surgeons on how symptomatic non-
toxic goiter affects patients referred for surgical interven-
tion, and of the expected improvements in HRQoL after sur-
gery. This might improve communication between patients, 
physicians, and surgeons before and after surgery and align 
the expectations. 
• This study will serve as a relevant comparison group for 
future studies investigating the effect of 131I, LFA, and RFA 
treatment on HRQoL in patients with benign nodular goiter. 
THYROIDECTOMY AND SWALLOWING DYSFUNCTION 
In addition to the profound improvements in Goiter Symptoms of 
the HRQoL study we also identified large improvements in the 
Goiter Symptoms scale in the sub-group of patients examined 
with HREM. We found no evidence that motility disturbances 
could explain swallowing difficulties before and after surgery.  
Problems with this arm of the study arose from the low 
number of patients and the lack of a control group, resulting in a 
poor quality prognostic cohort. The small number of patients and 
the missing control group were directly associated with the dis-
comfort of the examination which made it difficult to recruit 
patients and it increased the loss to follow-up. Given the low 
number of patients, attempts to perform sub-group analyses 
were not feasible. 
Regarding the internal validity of the HREM study, the 
blind interpretation of the motility examination supports the 
results. However, the Goiter Symptom scale was not validated 
specifically for the assessment of swallowing symptoms, giving 
some limitations in interpreting the findings. Only a direct com-
parison of this scale to other questionnaires specifically validated 
for the investigation of swallowing dysfunction could limit this 
uncertainty. The limited recruiting rate (28% after the exclusion 
criteria) and a high drop-out rate (20%) makes our study at risk of 
being underpowered and thus prevents us from identifying real 
changes in esophageal motility after surgery.  
Other studies have also found improved swallowing func-
tion after surgery [37, 79-81]. This strengthens our belief in the 
relevance of the Goiter Symptom scale to measure changes in 
swallowing function. With respect to motility changes after sur-
gery, only one other study has investigated esophageal motility 
before and 30-45 days after thyroidectomy using water manom-
etry [36]. No change was found in esophageal motility after sur-
gery, but there were some disturbances in the UES motility which 
improved after surgery. We found no signs of disturbances in the 
UES motility in our cohort, but this may have been because of the 
differences between water manometry and HREM. Our findings 
could preferably have been confirmed with other techniques 
investigating bolus transit directly. Although relevant, there is no 
information available on changes in esophageal motility after 131I, 
LTA or RFA treatment.  
Limitations 
Only 12% of patients with goiter referred for thyroidectomy, 
before exclusion criteria were applied, were included in the study, 
which severely limit our ability to generalize from our findings. 
Additionally, as HREM is a novel technique, many studies are 
continuously being published to validate the technique under 
various conditions and much information is still missing regarding 
the reliability of the examination. As an example, the reference 
values used for comparison were from a selected group of pa-
tients aged 20-49 years [166] which was not necessarily repre-
sentative for our group of patients with a mean age of 59.9 ± 11.8 
years.  
We experienced a larger frequency of drop-outs in the 
first half of the study compared to the latter half. This most likely 
reflected a learning curve in patient handling and did not affect 
the results of the individual patients which were analyzed blind. A 
different setup with more supervision might have prevented 
some patients from dropping out, and thus increasing the power 
of the study. The learning curve also led to faster examinations 
towards the end of the study. This could explain the observed 
increase in UES basal pressure, as this pressure decreases when 
patients are allowed a long phase of getting familiar with the 
catheter. By the end of the study the “getting familiar” phase was 
shorter than at the beginning of the study. Alternatively there 
could be pressure drift in the sensors, as explained in the meth-
ods section, or on esophageal decompression reducing the need 
for a high closing pressure. 
The use of a five mL water bolus in the supine position to 
assess swallowing is standardized practice for HREM analyses. 
This is not physiologically sound as patients rarely lie down when 
swallowing. However, as the swallowing complaints in patients 
with goiter often occur when patients are lying down, this might 
be suitable for examining our patient group. Nevertheless, we 
might have found more motility disturbances if we had used a 
more challenging bolus than water, such as apple sauce, cubed 
bread or marshmallows, but this is pure speculation.  
Implications 
• Swallowing dysfunction in patients with goiter is likely to be 
related to factors other than motility disturbances. 
• Thyroidectomy appears to be a safe procedure which does 
not affect esophageal motility negatively.  
THYROIDECTOMY AND AIRWAYS 
We found substantial improvements in airflow and a large reduc-
tion in tracheal compression in patients with large goiters after 
thyroidectomy. Patients with smaller goiters, i.e. volumes below 
100 mL, experienced much less impact on the trachea and air-
flow. The improvements in tracheal narrowing correlated with 
improvements in HRQoL. 
The results are supported by the following considerations: 
first, they are biologically plausible as the cartilage rings of the 
trachea can withstand some external pressure and probably also 
the pressure from a small goiter. Second, the increased airflow 
after surgery followed the principles of Poisseulle’s law, showing 
air flow to increase with reductions in tracheal narrowing. Third, 
other studies have similarly identified improvements in airflow 
after surgery [58, 82]. The features, in combination with an inclu-
sion rate over 50% and a low drop-out rate of 13%, enable us able 
to generalize from the study population. The internal validity of 
the study is acceptable as we used validated measuring modali-
ties such as MRI and the ThyPRO questionnaire.  
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Our patients experienced significant improvements in 
HRQoL after surgery. However, only the improvement in the 
Impaired Daily Life scale was associated with relief in tracheal 
narrowing, but interestingly not with improvements in airflow. 
This is puzzling, as the luminal area of the trachea is a surrogate 
marker of tracheal airflow. However, the ES related to changes in 
the airflow were small when compared to the moderate ES 
changes of tracheal anatomy. Hence, the greater variation in 
airflow parameters lead to smaller ES compared to trachea anat-
omy data. This might explain the lack of significant association 
between airflow and HRQoL parameters. These factors indicate 
that the UAO previously suggested to be severely underestimated 
[45] might not be that common in patients with goiter and cer-
tainly not of great significance to most patients. Many other 
factors besides the volume of the removed thyroid gland are 
likely to be involved in the improvements of HRQoL after thyroid 
surgery. 
It is interesting that no patient experienced a substantial 
increase in tracheal narrowing after surgery indicating that nei-
ther fibrotic tissue formation nor tracheomalacia was of great 
concern in patients undergoing thyroidectomy. Previous reports 
mentioned an ambiguous correlation between goiter volume and 
the degree of tracheal compression [83]. However, our data show 
a clear logarithmical correlation between goiter volume and 
tracheal narrowing, and thereby provide new knowledge of the 
basic physiology of goiter.  
No study has previously examined the impact of surgery 
on tracheal anatomy, but several studies using 131I have shown 
improvements in SCAT after reduction in goiter volume similar to 
our study [100, 104, 107, 163].   
Limitations 
A limitation to our data was the lack of a control group during FVL 
and MRI evaluations. The small reduction in FVC seen six months 
after surgery could have been an effect of changes in the FVL 
instruction across time and may therefore indicate bias. From the 
study design, these differences could not be controlled for in the 
analyses. In addition to the missing control group, the lack of 
blinding could also give rise to bias. In the MRI measurements, 
the fact that the examiner knew the outcome of the study could 
have led to overestimation of the study effects by as much as 17% 
[168-170]. However, as the observed differences in the study 
were larger than this percentage, this bias likely does not affect 
our results. Had the images been blinded it might have led to 
additional bias by making their evaluation less precise [171].  
The flow volume loop curve examination was obtained 
with patients in a seated position. However, this does not reflect 
the actual compression of goiter very well as the compression is 
most prominent during activity or when patients lie in the supine 
position as with the MRI scanning’s. Thus the changes in airflow 
might have been underestimated, thus explaining the small effect 
sizes of the airflow parameters and the lack of correlation to 
tracheal anatomy and HRQoL parameters. 
Post-surgically, all patients with a total thyroidectomy re-
ceived LT4, while this was only the case for 13% of patients un-
dergoing hemithyroidectomy. In a few patients serum TSH took 
months to normalize and 13% of the patients had serum TSH 
levels above or below the reference level six months after sur-
gery. It has been speculated that overt and even sub-clinical 
hypothyroidism, with the need for LT4 substitution after surgery, 
might affect respiratory function negatively [172]. We found no 
evidence to support this claim, as there was no correlation be-
tween pulmonary function parameters and TSH or LT4 substitu-
tion.  
Implications 
• Patients with a small goiter do not seem to have tracheal 
compression. This is primarily seen in patients with goiters > 
100 mL, which is quite rare in areas with good access to 
healthcare.  
• As the majority of patients with symptomatic goiter re-
ferred for thyroidectomy at our facility do not suffer from 
UAO, it might not be as severely underestimated as previ-
ously expected.  
GENERALIZABILITY 
The inclusion and exclusion criteria limited the number of pa-
tients available for examination and thereby reduced the general-
izability of our results. The first inclusion criterion requiring pa-
tients with symptomatic goiter prior to undergoing thyroidectomy 
excluded patients with goiters not causing symptoms, patients 
who rejected surgical treatment, and patients with thyroid malig-
nancy. This introduced a selection bias into the cohort, which 
makes us unable provide strong conclusions with regard to the 
correlation between goiter volume and symptoms. The second 
inclusion criterion requiring patients to read and understand 
Danish, excluded most patients with an ethnic background other 
than Danish. This criterion was introduced a few months into the 
inclusion period as we experienced difficulties in explaining the 
study protocol and especially the nature of the informed consent 
for patients, to people with an ethnic background other than 
Danish. Despite its relevance, this problem is well known in re-
search and difficult to address [173].  
The exclusion criteria of: 1) previous surgery to the neck, 
2) suspicion of thyroid cancer or present cancer, 3) age below 20 
years or age above 80 years, 4) neuromuscular diseases including 
diabetes mellitus, and 5) pre-operative overt hypothyroidism and 
overt hyperthyroidism, all limited the generalizability of our re-
sults. The overt hyperthyroidism exclusion criterion excluded a 
few very large goiters with thyroid nodule autonomy, thereby 
reducing the number of patients with very large goiters. However, 
this was intended, as thyroid dysfunction can itself have a pro-
found impact on HRQoL [174, 175]. The exclusion criterion of 
neuromuscular disease including diabetes mellitus was chosen for 
the HREM examination, as neuromuscular disease can affect 
HREM results and approximately 51% of patients with diabetes 
are known to have esophageal motility disturbances. This exclud-
ed many patients with multi-morbidity from participating and led 
to a healthier study population than would otherwise have been 
recruited [176]. Further, it precluded us from extrapolating our 
results to patients with diabetes. This was especially problematic 
as insulin resistance is an independent risk factor for developing 
goiter [25-31]. Retrospectively, this criterion should have been an 
exclusion criterion only for the HREM study or preferably not 
have been used at all, as the study objectives investigated chang-
es in disturbances and not the prevalence.   
A few of our patients had insufficiently adjusted TSH six 
months after surgery. How this influenced the results is unknown, 
but the improvements in HRQoL might have been underestimated 
compared to a patient cohort with well-adjusted TSH levels. As 
thyroid hormones affect all tissue this could have had unknown 
implications for the HREM and MRI study. However, this is pure 
speculation and our data does not indicate any impact of this 
limitation. Throughout the study all TSH variables were collected 
 DANISH MEDICAL JOURNAL   14 
from chart reviews, meaning that the day of blood sampling was 
not necessarily close to the study visits. This limits us from making 
a strong conclusion on the impact of TSH and post-operative 
changes in symptoms and physiological parameters. 
Lastly our data cannot be transferred to other groups of 
patient with e.g. toxic nodular goiter, Grave’s disease or autoim-
mune hypothyroid disease, as these were not covered by our 
inclusion criteria. A separate study could determine the impact of 
thyroidectomy on these diseases. 
Despite the above limitations our study has some distinct 
advantages. First, we used a group of patients selected for their 
disease (benign nodular goiter) instead of the procedure (thy-
roidectomy), which made it easier for patients and doctors to 
interpret the results in relation to the individual patient. Second, 
by consecutive recruitment of patients with thyroid nodularity 
with no regard to the volume of the goiter, our results reflected 
the actual situation in the clinic with many patients having rather 
small goiters and some even thyroid nodularity as their main 
complaint. A larger effect might have been observed if patients 
with large goiters or patients undergoing total thyroidectomy had 
been exclusively recruited. Lastly, the study was implemented in a 
daily clinic without selecting surgeons or changing the follow-up 
program, hence the results accurately reflected the clinical situa-
tion.   
CONCLUSIONS 
Patients with benign non-toxic nodular goiter experienced a 
lower HRQoL compared to the general population before surgery. 
We found strong evidence for the beneficial effect of thyroid 
surgery for relieving compressive symptoms and returning HRQoL 
to a level close to the general population. This effect was of a 
magnitude not easily attributed to confounding factors.  
The swallowing difficulties of patients with goiter seemed 
to be caused by other factors than motility disturbances, as evi-
dent from the normal esophageal motility observed in the study 
cohort before and after surgery. The reasons for the pronounced 
swallowing symptoms should be sought in other mechanisms 
affecting the esophagus.  
Previously, UAO has been suggested to be severely un-
derestimated in patients with goiter. From our data, UAO seems 
to be uncommon, especially in patients with smaller goiters. 
However, in patients with very large goiters the surgical removal 
of goiter has a profound and positive impact on tracheal com-
pression and airflow, and additionally improves some aspects of 
HRQoL. 
From this project, patients, physicians, and surgeons 
should gain better knowledge of the impact of goiter and surgical 
treatment on HRQoL, swallowing dysfunction, and affection of 
tracheal anatomy and airflow, all of which could be used in the 
daily consultations. 
FUTURE RESEARCH 
Future studies requiring recruitment of new patients are indeed 
of great interest. Here a direct comparison of 131I, LTA or RFA to 
thyroidectomy would be a clear benefit for both patients and 
clinicians. In addition, the impact of non-surgical interventions 
RFA and LTA needs more attention as these technologies have the 
potential to disrupt the present practice of performing surgery on 
patients with very small goiters. Such as study, should be per-
formed with the ThyPRO questionnaire as the primary endpoint, 
but should preferably also include information on major compli-
cations such as post-treatment voice changes. We would suggest 
performing this study in patients with goiters below 100 ml, as 
this is the most prevalent patient group, which rarely suffers from 
tracheal compression.  
A future project constructing an evidence-based shared 
decision making tool presenting the benefits and risks associated 
with the various treatments for patients with benign nodular 
goiter, would provide relevant information to clinicians.  
This study did not identify any changes in esophageal mo-
tility despite patient complaints of swallowing dysfunction. An 
obvious next project is to investigate the impact of local esopha-
geal compression from goiter on the Goiter Symptom scale of the 
ThyPRO questionnaire.  The study can be performed on our exist-
ing MRI scans, collected ThyPRO data, and would be a novel 
addition to the literature. The outcome would be a secondary 
outcome utilizing previous data, but nonetheless relevant for 
publication  
Previous studies have suggested that UAO may be over-
looked in patients with goiter if patients have no respiratory 
complaints [45]. Our findings suggest that UAO is rare in patients 
with symptomatic goiter. Based on our findings, the previously 
suggested method to identify UAO in patients with goiter by 
applying cut-off limits on FVL parameters appears to be an inap-
propriate way forward [153] 
Suggested cut-off limit for identifying UAO:           
min
81
L
mL
PEF
FEV
>
  
[153] 
The suggested cut-off limit is based on an old study using mouth-
pieces with very small orifices (0.5 cm2) to simulate UAO [177]. 
These mouth pieces are only comparable to the trachea the very 
few patients with goiters >300 mL in our study. The existing data 
from the MRI study might therefore be used to challenge the 
validity of this cut-off limit, preferably, in corporation with other 
researchers in possession of tracheal imaging data of patients 
with goiter.   
 
SUMMERY 
Surgery: Is it any Good for Goiter? In patients with goiter the 
benefits of thyroid surgery have previously rarely been investi-
gated, as only few alternatives existed. However, the increasing 
evidence of the advantages with non-surgical substitutes with 
lower costs and preferable risk profiles prompted us to investi-
gate the evidence base for thyroid surgery thoroughly. This thesis 
consists of three published studies investigating the impact of 
thyroidectomy on: 1) changes in disease-specific quality of life, 2) 
swallowing symptoms and esophageal motility, and 3) tracheal 
anatomy and airflow, in a cohort of patients with benign nodular 
goiter. 
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